Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.
With many disease-causing bacteria ratcheting up their shields against current drugs, new tactics are vital to protect people from treatment-resistant infections.
The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers' diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.
In one of the largest studies to measure the burden of antibiotic resistance in a low- or middle-income country, researchers at the Center for Disease Dynamics, Economics & Policy report that in-hospital mortality is significantly higher among patients infected with multi-drug resistant or extensively drug resistant pathogens including Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii.
More and more bacteria are resistant to available antibiotics. A team of chemists from the Technical University of Munich now presents a new approach: they have identified important enzymes in the metabolism of staphylococci. Blocking these enzymes in a targeted manner would allow the pathogens to be starved.
An antibiotic called thanatin attacks the way the outer membrane of Gram-negative bacteria is built. Researchers at the University of Zurich have now found out that this happens through a previously unknown mechanism. Thanatin, produced naturally by the spined soldier bug, can therefore be used to develop new classes of antibiotics.
The treatment of intestinal infections caused by some strains of the bacterium Escherichia coli, present in unsanitized or contaminated foods, may have a new ally.
TGen North, the Pathogen and Microbiome Division of the Translational Genomics Research Institute, has partnered with the non-profit NARBHA Institute to advance human health through the new TGen One Health Collaborative, an initiative that recognizes the interdependence of people, animals and plants in both the human-built and natural environments.
While making smart glue, a team of engineers discovered a handy byproduct: hydrogen peroxide. In microgel form, it reduces bacteria and virus ability to infect by at least 99 percent.
A new antibiotic hailed as the "last line of defense" in the battle against drug-resistant superbugs such as MSRA and VRE is taking the next step in development thanks to a UK Government grant of almost £500,000.
Healthcare professionals nationwide are gathering this week to discuss how to improve programs to better control antibiotic use in healthcare facilities.
If patients return to Dr. Crystal Bowe soon after taking medication for a sexually transmitted infection, she usually knows the reason: Their partners have re-infected them.
Nearly two thirds of Americans (65%) say antibiotic resistance is a public health problem and a strong majority (81%) say they are concerned that antibiotic resistance will make more infections difficult or impossible to treat and even deadly, according to a national public opinion survey commissioned by Research!America in collaboration with the Infectious Disease Society of America.
The World Health Organization (WHO) has released a notification regarding antibiotic usage and resistance this week. The organization has warned that some countries have a very high consumption of antibiotics and there is a shortage in several regions worldwide. This disparity has led to misuse that had spread antibiotic resistance, the WHO says.
Experts from across Europe have developed a set of competencies in antimicrobial prescribing and stewardship, using a structured consensus procedure.
Brazil's Ministry of Health received reports of 11,524 outbreaks of foodborne diseases between 2000 and 2015, with 219,909 individuals falling sick and 167 dying from the diseases in question.
A phase 2 clinical trial led by Stephanie N. Taylor, MD, Professor of Medicine and Microbiology in the Section of Infectious Diseases at LSU Health New Orleans School of Medicine, has found that a new antibiotic effectively treats uncomplicated urogenital and rectal gonorrhea infections in a single oral dose.
Against this background, the German Federal Institute for Risk Assessment is organising two symposia dealing with microbial risks in food in November 2018: "Food-associated viruses" on 7 November and "Antimicrobial resistance in the food chain" on 8/9 November.
When Chlamydia trachomatis, the bacterium that causes one of the most common sexually transmitted infections worldwide, infects a human cell, it hijacks parts of the host to build protective layers around itself.
The World Health Organization considers Pseudomonas aeruginosa a germ requiring urgent action to prevent and control its spread. The bacteria can cause a variety of diseases from chronic lung infections to sepsis.
An investigational oral antibiotic called zoliflodacin was well-tolerated and successfully cured most cases of uncomplicated gonorrhea when tested in a Phase 2 multicenter clinical trial, according to findings published today in the New England Journal of Medicine.